Have a feature idea you'd love to see implemented?
Let us know!
SCPH scPharmaceuticals Inc
Price (delayed)
$4.18
Market cap
$209.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.56
Enterprise value
$211.98M
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships,
Highlights
The revenue rose by 36% since the previous quarter
scPharmaceuticals's gross profit has increased by 35% QoQ
The equity has plunged by 85% YoY and by 62% from the previous quarter
The company's quick ratio has shrunk by 78% YoY and by 34% QoQ
Key stats
What are the main financial stats of SCPH
Market
Valuations
Earnings
Shares outstanding
50.03M
Market cap
$209.12M
Enterprise value
$211.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
16.29
Price to sales (P/S)
6.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.81
Revenue
$24.05M
EBIT
-$52.26M
EBITDA
-$51.74M
Free cash flow
-$66.57M
Per share
Balance sheet
Liquidity
EPS
-$1.56
Free cash flow per share
-$1.71
Book value per share
$0.26
Revenue per share
$0.62
TBVPS
$1.68
Total assets
$65.46M
Total liabilities
$56.21M
Debt
$41.36M
Equity
$9.25M
Working capital
$49.7M
Debt to equity
4.47
Current ratio
4.84
Quick ratio
3.45
Net debt/EBITDA
-0.06
Margins
Efficiency
Dividend
EBITDA margin
-215.2%
Gross margin
71.2%
Net margin
-252.2%
Operating margin
-251.1%
Return on assets
-70.4%
Return on equity
-201.8%
Return on invested capital
-75%
Return on capital employed
-99.5%
Return on sales
-217.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SCPH stock price
How has the scPharmaceuticals stock price performed over time
Intraday
-4.35%
1 week
-4.78%
1 month
-12.37%
1 year
-26.15%
YTD
-33.33%
QTD
-8.33%
Financial performance
How have scPharmaceuticals's revenue and profit performed over time
Revenue
$24.05M
Gross profit
$17.11M
Operating income
-$60.38M
Net income
-$60.64M
Gross margin
71.2%
Net margin
-252.2%
SCPH's net margin has soared by 79% YoY and by 23% QoQ
scPharmaceuticals's operating margin has soared by 79% YoY and by 26% from the previous quarter
The revenue rose by 36% since the previous quarter
scPharmaceuticals's gross profit has increased by 35% QoQ
Growth
What is scPharmaceuticals's growth rate over time
Valuation
What is scPharmaceuticals stock price valuation
P/E
N/A
P/B
16.29
P/S
6.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.81
The company's EPS fell by 18% YoY and by 5% QoQ
The equity has plunged by 85% YoY and by 62% from the previous quarter
The price to book (P/B) is 83% more than the last 4 quarters average of 8.9
SCPH's price to sales (P/S) is 63% lower than its last 4 quarters average of 18.2
The revenue rose by 36% since the previous quarter
Efficiency
How efficient is scPharmaceuticals business performance
SCPH's ROE has dropped by 173% year-on-year and by 52% since the previous quarter
The company's return on sales has surged by 79% YoY and by 23% QoQ
The return on assets has dropped by 63% year-on-year and by 20% since the previous quarter
scPharmaceuticals's return on invested capital has decreased by 17% YoY and by 13% QoQ
Dividends
What is SCPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SCPH.
Financial health
How did scPharmaceuticals financials performed over time
The company's total assets is 16% higher than its total liabilities
The company's quick ratio has shrunk by 78% YoY and by 34% QoQ
The current ratio has plunged by 72% YoY and by 22% from the previous quarter
SCPH's debt to equity has surged by 169% since the previous quarter
The equity has plunged by 85% YoY and by 62% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.